Immuneering doses first subject in Phase I/IIa solid tumour trial
Immuneering has dosed the first subject in its Phase I/IIa clinical trial of IMM-6-415 for the treatment of advanced solid tumours with specific genetic mutations. A deep cyclic inhibitor (DCI) of the mitogen-activated protein kinase (MAPK) pathway, …